Emgality cut weekly cluster headache attacks in half or more for most patients at Week 31
71.4% of patients on Emgality achieved a ≥50% reduction from baseline vs 52.6% of patients on placebo1
ap=0.046 vs placebo
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0089. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0088. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0087. 5. Data on File. Lilly USA, LLC. DOF-GZ-US-0093.